Zura Bio Ltd ZURA

$3.99 +0.05 (1.27%)

Valuation

Market cap
387,149,000
Revenue TTM
$0
Net income TTM
$-99,350,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
1,930,200
Avg volume
3,272,612
Day's range
$3.90 – $4.13
Shares out
95,829,000
Stochastic %K
50%
Beta
0.01
Analysts
Strong Buy
Price target
$18.83

Price

Company profile

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880...

Show more

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.

Industry
Biotechnology
Sector
Healthcare
Phone
702 825 9872
Website
https://zurabio.com
Address
1489 W. Warm Springs Road, Suite 110, Henderson, United States

Latest news

Stocktwits

WhiteFang420 Nov 2, 8:48 PM
$ZURA in here today. Small size very risky, could be a banger though.
0 replies
JF55 Nov 2, 7:32 PM
$ZURA IL17A-deficient mice show robust protection in autoimmune models. IL17F-deficient mice do not. Genetic inhibition predicts the effects of pharmacological inhibition. Tibulizumab's IL17A action alone may be enough, even without BAFF. As Adam May points out, the whole Bimzelx IL17F issue may be a red herring due to prior underdosing with Talz. Good bet here at current prices. The mice agree
0 replies
Aombeus Nov 2, 2:47 PM
$ZURA data could be released AH
0 replies
NVDAMillionaire Nov 2, 8:38 AM
$ZURA Brilliant piece that captures ZURA's situation perfectly. So if you want to update your understanding of ZURA or get to know ZURA better, this is essential reading. https://everyticker.com/quote/ZURA/analysis/clinical-inflection-meets-balance-sheet-strength-at-zura-bio-nasdaq-zura
0 replies
Merlintrader Oct 31, 6:26 PM
$ZURA closed the week at $4.04 (+20.2% w/w, +4.9% Friday), below the 50-day SMA ($4.66) and below the 200-day ($5.24). RSI14 48.1. Support $3.27, resistance $4.78 (20-day range, middle). New hub updated: https://www.merlintrader.com/zura-bio-stock-hub/
0 replies
SearchFor911 Oct 30, 7:37 PM
$ZURA someone hopes something
0 replies
Aombeus Oct 30, 7:14 PM
$ZURA someone knows something
0 replies
Aombeus Oct 30, 4:45 PM
$ZURA data could be released AH
1 replies